BioSpace News Archive

Achieved goal of establishing ULTOMIRIS® (ravulizumab-cwvz) as new standard of care in PNH with more than 70% patient conversion from SOLIRIS® (eculizumab) in U.S.

Teleflex Incorporated announced that its Board of Directors declared a quarterly cash dividend of thirty-four cents per share of common stock.

Obalon Therapeutics, Inc., a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announced its financial results for the second quarter ended June 30, 2020.

FDA Grants Priority Review to Supplemental Biologics License Application (sBLA) for KEYTRUDA Plus Chemotherapy for the Treatment of Certain Patients With Metastatic TNBC Based on KEYNOTE-355 Trial

Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for its investigational drug pevonedistat for the treatment of patients with higher-risk myelodysplastic syndromes.

ANI Pharmaceuticals, Inc. announced that the Company will release its second quarter 2020 financial results on Thursday, August 6, 2020, before the opening of the U.S. financial markets.

Codexis, Inc., a leading protein engineering company, announces that it will report second quarter 2020 financial results after market close on Thursday, August 6, 2020.

Axsome to host conference call and webcast on Monday, August 10, 2020 at 8:00 AM Eastern Time

IMARA Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, announced the U.S. Food and Drug Administration has granted Fast Track designation and Rare Pediatric Disease designation for its lead clinical asset, IMR-687, for the treatment of beta-thalassemia.

Second Quarter TIBSOVO® Net Revenue of $27.6 Million; Company Reiterates 2020 TIBSOVO® Net U.S. Revenue Guidance of $105–115 Million